The risk of asthma mortality with inhaled long acting β-agonists

Postgraduate Medical Journal

Volumn 84, Issue 995, 2008, Pages 467-472

  Wijesinghe, M ^a   Perrin, K ^a   Harwood, M ^a   Weatherall, M ^b   Beasley, Richard ^a,c  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; PLACEBO; SALBUTAMOL; SALMETEROL; THEOPHYLLINE;

ARTIFICIAL VENTILATION; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG FATALITY; HUMAN; MONOTHERAPY; MORTALITY; PRACTICE GUIDELINE; RESPIRATORY TRACT INTUBATION; REVIEW; RISK FACTOR; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; ETHANOLAMINES; HUMANS; META-ANALYSIS AS TOPIC; MORTALITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; YOUNG ADULT;

EID: 55349109280     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2007.067165     Document Type: Review

References (53)

1. Benson RL, Perlman F. Clinical effects of epinephrine by inhalation. Allergy 1948;19:129-40.
2. Van Metre TE. Adverse effects of inhalation of excessive amounts of nebulised isoproterenol in status asthmaticus. J Allergy 1969;43:101-13.
3. Speizer FE, Doll R. A century of asthma deaths in young people. BMJ 1968;3:245-6.
4. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. BMJ 1968;1:335-9.
5. Inman WHW, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969;ii:279-85.
6. Stolley PD. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972;105:883-90.
7. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: a case control study. Lancet 1989;i:917-22.
8. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
9. Crane J, Pearce N, Burgess C, et al. Asthma and the β agonist debate. Thorax 1995;50(Suppl 1):S5-10.
10. Pearce N, Beasley R, Crane J, et al. Epidemiology of asthma mortality. In: Holgate ST, Busse WW, eds. Asthma and rhinitis. 2nd ed. Oxford: Blackwell Scientific Press, 2000:58-69.
11. Martinez FD. Safety of long-acting beta-agonists - an urgent need to clear the air. N Engl J Med 2005;353:2637-9.
12. Glassroth J. The role of long-acting β-agonists in the management of asthma: analysis, meta-analysis and more analysis. Ann Intern Med 2006;144:936-7.
13. 2-agonists. Eur Respir J 2006;28:900-2.
14. Nelson HS. Long-acting beta-agonists in adult asthma: evidence that these drugs are safe. Prim Care Respir J 2006;15:271-7.
15. Ernst P, Mclvor A, Ducharme FM, et al for the Canadian Asthma Guideline Group. Safety and effectiveness of long-acting inhaled β-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006;145:692-4.
16. Salpeter S. Safety of long-acting β-agonists. Ann Intern Med 2006;145:708-10.
17. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7.
18. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
19. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2006. www.ginasthma.org (accessed March 2008).
20. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma: a national clinical guideline. November 2005. www.enterpriseportal2.co.uk/filestore/bts/ asthmaupdatenov05.pdf (accessed March 2008).
21. Pearca NE. Crane J. Epidemiological methods for studying the role of beta receptor agonist therapy in asthma mortality. In: Beasley R. Pearce NE, eds. The role of beta agonist therapy in asthma mortality. New York: CRC Press, 1993:68-83.
22. Andersen HR, Ayres JG, Sturdy PM, et al for the Mortality and Severe Morbidity Group of the National Asthma Task Force. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005;330:117-23.
23. Travers JJ, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007;62:219-23.
24. Maringa C, Rickard K, DiSantostefano R, et al. Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care. European Respiratory Society Annual Congress 2007 (Abstract).
25. Lanes SF, Garcia Rodriguez LA, Hueta C. Respiratory medications and risk of asthma death. Thorax 2002;57:683-6.
26. Williams C, Crossland L, Finnerty J, et al. Case-control study of salmeterol and nearfatal attacks of asthma. Thorax 1998;53:7-13.
27. Lanes SF, Lanza LL, Wentworth III CE. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med 1998;158:857-61.
28. Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997;52:612-7.
29. Salpeter SR, Buckley NS, Orniston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-12.
30. Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005:CD005535 [PMID: 16235410].
31. Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005:CD005533 [PMID: 16235409].
32. Crane J, Pearce N, Burgess C, et al. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 1992;21:737-44.
33. Rea HH, Scragg R, Jackson R, et al. A case-control study of deaths from asthma. Thorax 1986;41:833-9.
34. Ryan G, Musk AW, Perera DM, et al. Risk factors for death in patients admitted to hospital with asthma: a follow-up study. Aust NZ J Med 1991;21:681-5.
35. Masoli M, Weatherall M, Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730-4.
36. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-73.
37. Nelson HS, Beasley R, Yancey SW, et al. No increase in asthma-related hospitalizations following the addition of salmeterol to an inhaled corticosteroid in patients with asthma: a meta-analysis. An J Respir Crit Care Med 2007;175:A59.
38. Mann M, Choudhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003;134:70-4.
39. Wolfe J, LaForce C, Friedman B, et al. Formoterol 24 μg bid, and serious asthma exacerbations: similar rates compared with formoterol. 12 μg bid, with and without extra doses taken on demand, and placebo. Chest 2006;129:27-38.
40. Jaeschke R, Mejza F, Lesniak W, et al. The safety of formoterol among patients with asthma using inhaled corticosteroids. Am J Respir Crit Care Med 2007;175:A57.
41. Nelson HS, Dorinsky PM. Safety of long-acting β-agonists. Ann Intern Med 2006;145:706.
42. Centers for Disease Control and Prevention. CDC Compressed mortality data: underlying causes of death. http://wonder.cdc.gov/mortSQL.html (accessed March 2008).
43. Nelson H, Yancey S, Kral K, et al. SMART and asthma-related mortality: extrapolations based upon US asthma death rate. Chest 2001;130(Suppl):835.
44. Anderson RN, Minino AM, Hoyert DL, et al. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. National Vital Statistics Reports 2001;49:1-31.
45. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med 2005;99:1263-7.
46. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004;113:245-51.
47. Larsen GL Differences between adult and childhood asthma. J Allergy Clin Immunol 2000;106(3 Suppl):S153-S157.
48. Bisgaard H, Szefler S. Long-acting beta2 agonists and paediatric asthma. Lancet 2006;367:286-8.
49. Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003;36:391-8.
50. Calverley PM, Anderson JA. Celli B, et al for the TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
51. Busse W, Koenig SM, Oppenheimer J, et al. Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily. J Allergy Clin Immunol 2003;111:57-65.
52. Lalloo UG, Malotepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003;123:1480-7.
53. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2007. www.goldcopd.com (accessed 11 June 2008).